##chargement des packages----
library(questionr)
library(tidyverse)
## ── Attaching core tidyverse packages ──────────────────────── tidyverse 2.0.0 ──
## ✔ dplyr 1.1.1 ✔ readr 2.1.4
## ✔ forcats 1.0.0 ✔ stringr 1.5.0
## ✔ ggplot2 3.4.2 ✔ tibble 3.2.1
## ✔ lubridate 1.9.2 ✔ tidyr 1.3.0
## ✔ purrr 1.0.1
## ── Conflicts ────────────────────────────────────────── tidyverse_conflicts() ──
## ✖ dplyr::filter() masks stats::filter()
## ✖ dplyr::lag() masks stats::lag()
## ℹ Use the conflicted package (<http://conflicted.r-lib.org/>) to force all conflicts to become errors
library(tableone)
library(labelled)
library(gtsummary)
library(GGally)
## Registered S3 method overwritten by 'GGally':
## method from
## +.gg ggplot2
library(readxl)
library(effects)
## Le chargement a nécessité le package : carData
## lattice theme set by effectsTheme()
## See ?effectsTheme for details.
library(survival)
library(survminer)
## Le chargement a nécessité le package : ggpubr
##
## Attachement du package : 'survminer'
##
## L'objet suivant est masqué depuis 'package:survival':
##
## myeloma
library(ggplot2)
library(dplyr)
library(knitr)
library(cowplot)
##
## Attachement du package : 'cowplot'
##
## L'objet suivant est masqué depuis 'package:ggpubr':
##
## get_legend
##
## L'objet suivant est masqué depuis 'package:lubridate':
##
## stamp
##chargement des données
library(readxl)
informations <- read_excel("informations.xlsx")
## New names:
## • `Dosage (mg/j)` -> `Dosage (mg/j)...13`
## • `Dosage (mg/j)` -> `Dosage (mg/j)...15`
##recodage des variables et bases de données le cas échéant----
##renommer des variables pour présentation dans les tableaux de résultat
##
##tableau descriptif patients ----
tbl_summary(
informations, include = c("Age", "Sexe", "Maladie",
"Mutation", "anticancereux_prescrit","ligne.cat",
"comedication","n_comedication" ,"tac"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 132 |
Age |
68 [28 - 88] |
Sexe |
|
F |
81 (61.4%) |
M |
51 (38.6%) |
Maladie |
|
Adénocarcinome |
126 (95.5%) |
Carcinome épidermoïde |
3 (2.3%) |
Thymome |
2 (1.5%) |
Tumeurs neuroendocrines digestives et pulmonaires |
1 (0.8%) |
Mutation |
|
ALK |
26 (19.7%) |
ALK BRAF |
1 (0.8%) |
Aucune |
7 (5.3%) |
BRAF |
7 (5.3%) |
EGFR |
64 (48.5%) |
EGFR MET |
2 (1.5%) |
HER2 |
1 (0.8%) |
KIF5 B-RET |
1 (0.8%) |
KRAS |
14 (10.6%) |
MET |
2 (1.5%) |
RET |
1 (0.8%) |
ROS1 |
6 (4.5%) |
anticancereux_prescrit |
0 (NA%) |
Unknown |
132 |
ligne.cat |
|
1 |
19 (25.3%) |
2 |
19 (25.3%) |
3 et plus |
37 (49.3%) |
Unknown |
57 |
comedication |
|
Non |
5 (3.8%) |
Oui |
127 (96.2%) |
n_comedication |
6.0 [0.0 - 21.0] |
tac |
|
IM |
1 (0.8%) |
Non |
83 (62.9%) |
Oui |
48 (36.4%) |
##tableau descriptif activité pharmacie ----
tbl_summary(
informations, include = c("consultation_initiale", "analyse_pharmaceutique",
"cr_analys_pharma_envoye", "delai_consult_pharma", "envoi_evaluable",
"oncologue_destinataire_cr","ide_destinataire_cr", "officine_destinataire_cr",
"med_t_destinataire_cr", "consult_toxicite"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 132 |
consultation_initiale |
|
Non |
124 (93.9%) |
Oui |
8 (6.1%) |
analyse_pharmaceutique |
|
Non |
12 (9.1%) |
Oui |
120 (90.9%) |
cr_analys_pharma_envoye |
|
IM |
30 (22.7%) |
Non |
15 (11.4%) |
Oui |
87 (65.9%) |
delai_consult_pharma |
4 [-10 - 725] |
Unknown |
16 |
envoi_evaluable |
|
Non |
13 (9.8%) |
Oui |
119 (90.2%) |
oncologue_destinataire_cr |
|
IM |
40 (30.3%) |
Non |
15 (11.4%) |
Oui |
77 (58.3%) |
ide_destinataire_cr |
|
IM |
40 (30.3%) |
Non |
26 (19.7%) |
Oui |
66 (50.0%) |
officine_destinataire_cr |
|
IM |
40 (30.3%) |
Non |
82 (62.1%) |
Oui |
10 (7.6%) |
med_t_destinataire_cr |
|
IM |
41 (31.1%) |
Non |
91 (68.9%) |
consult_toxicite |
|
Non |
65 (49.2%) |
Oui |
67 (50.8%) |
##Retours des analyses pharmaceutiques
##chargement des données
analyse_pharma <- read_excel("analyse_pharma.xlsx")
##description des interactions globales
tbl_summary(
analyse_pharma, include = c("interaction_retrouvee", "Proposition_STP", 'intervention_pharmacien'),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 566 |
interaction_retrouvee |
|
Absence d'AP |
13 (2.3%) |
Non |
23 (4.1%) |
Oui |
530 (93.6%) |
Proposition_STP |
|
Oui |
54 (100.0%) |
Unknown |
512 |
intervention_pharmacien |
|
Adaptation plan de prise |
171 (32.9%) |
Arrêt comédication |
16 (3.1%) |
Modification posologique anticancéreux |
7 (1.3%) |
Modification posologique comédication |
4 (0.8%) |
Optimisation en fonction des indications |
1 (0.2%) |
Substitution comédication |
3 (0.6%) |
Surveillance renforcée EI |
318 (61.2%) |
Unknown |
46 |
##interactions anticancéreux sur comed
atk_comed<-filter(analyse_pharma, c(type_interaction=="Anticancéreux sur comédication"))
tbl_summary(
atk_comed, include = c("risque_interaction", "anticancereux_concerne", "cat_atc"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 359 |
risque_interaction |
|
Diminution efficacité comédication |
215 (59.9%) |
Majoration toxicité comédication |
99 (27.6%) |
Majoration toxicité ou diminution efficacité comed |
41 (11.4%) |
Potentialisation d'EI |
4 (1.1%) |
anticancereux_concerne |
|
Afatinib |
1 (0.3%) |
Alectinib |
1 (0.3%) |
Alectinib (métabolite actif) |
1 (0.3%) |
Brigatinib |
26 (7.2%) |
Cabozantinib |
8 (2.2%) |
Crizotinib |
20 (5.6%) |
Dabrafénib |
35 (9.7%) |
Evérolimus |
8 (2.2%) |
Lorlatinib |
46 (12.8%) |
Mobocertinib |
9 (2.5%) |
Osimertinib |
157 (43.7%) |
Sotorasib |
45 (12.5%) |
Tramétinib |
2 (0.6%) |
cat_atc |
|
Agents acting on the renin |
10 (2.8%) |
Analgesics |
76 (21.2%) |
Anesthetics |
4 (1.1%) |
ANTI-ACNE PREPARATIONS |
2 (0.6%) |
Antianemic preparations |
2 (0.6%) |
Antibacterials for systemic use |
1 (0.3%) |
Antidiarrheals, intestinal antiinflammatory/antiinfective agents |
6 (1.7%) |
Antiemetics and antinauseants |
5 (1.4%) |
Antiepileptics |
6 (1.7%) |
Antigout preparations |
3 (0.8%) |
Antihistamines for systemic use |
1 (0.3%) |
Antithrombotic agents |
15 (4.2%) |
Beta blocking agents |
15 (4.2%) |
Calcium channel blockers |
15 (4.2%) |
Cardiac therapy |
5 (1.4%) |
Corticosteroids for systemic use |
36 (10.0%) |
Cough and cold preparations |
1 (0.3%) |
Diuretics |
15 (4.2%) |
DRUGS FOR ACID RELATED DISORDERS |
34 (9.5%) |
Drugs for functional gastrointestinal disorders |
1 (0.3%) |
Drugs for obstructive airway diseases |
9 (2.5%) |
Drugs used in diabetes |
1 (0.3%) |
Endocrine therapy |
1 (0.3%) |
Laxatives |
7 (1.9%) |
Lipid modifying agents |
32 (8.9%) |
Psychoanaleptics |
15 (4.2%) |
Psycholeptics |
36 (10.0%) |
Urologicals |
5 (1.4%) |
#sources interactions
tbl_summary(
atk_comed, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1",
"OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19",
"CYP3A", "absorption"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 359 |
BCRP |
|
Modéré |
1 (0.3%) |
Non |
326 (90.8%) |
Oui |
32 (8.9%) |
P-gp |
|
Modéré |
24 (6.7%) |
Non |
312 (86.9%) |
Oui |
23 (6.4%) |
MATE1 |
|
Non |
358 (99.7%) |
Oui |
1 (0.3%) |
MRP2 |
|
Non |
351 (97.8%) |
Oui |
8 (2.2%) |
OAT3 |
|
Non |
355 (98.9%) |
Oui |
4 (1.1%) |
OATP1 |
|
Non |
358 (99.7%) |
Oui |
1 (0.3%) |
OATP1B1 |
|
Non |
357 (99.4%) |
Oui |
2 (0.6%) |
OATP1B3 |
|
Non |
355 (98.9%) |
Oui |
4 (1.1%) |
OTC2 |
|
Non |
358 (99.7%) |
Oui |
1 (0.3%) |
CYP2C8 |
|
Non |
358 (99.7%) |
Oui |
1 (0.3%) |
CYP2C9 |
|
Faible |
2 (0.6%) |
Non |
354 (98.6%) |
Oui |
3 (0.8%) |
CYP2C19 |
|
Faible |
2 (0.6%) |
Non |
357 (99.4%) |
CYP3A |
|
Faible |
149 (41.5%) |
Modéré |
71 (19.8%) |
Non |
89 (24.8%) |
Oui |
50 (13.9%) |
absorption |
|
Absorption |
2 (0.6%) |
Non |
357 (99.4%) |
##interactions comed sur atk
comed_atk<-filter(analyse_pharma, c(type_interaction=="Comédication sur anticancéreux"))
tbl_summary(
comed_atk, include = c("risque_interaction", "anticancereux_concerne", "cat_atc"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 151 |
risque_interaction |
|
Diminution efficacité anticancéreux |
35 (24.8%) |
Majoration toxicité anticancéreux |
102 (72.3%) |
Potentialisation d'EI |
4 (2.8%) |
Unknown |
10 |
anticancereux_concerne |
|
Afatinib |
8 (5.3%) |
Alectinib |
1 (0.7%) |
Alectinib + mtb actif |
1 (0.7%) |
Brigatinib |
5 (3.3%) |
Cabozantinib |
7 (4.6%) |
Crizotinib |
8 (5.3%) |
Dabrafénib |
11 (7.3%) |
Evérolimus |
7 (4.6%) |
Lenvatinib |
1 (0.7%) |
Lorlatinib |
6 (4.0%) |
Mobocertinib |
6 (4.0%) |
Osimertinib |
69 (45.7%) |
Sotorasib |
13 (8.6%) |
Tramétinib |
8 (5.3%) |
cat_atc |
|
Agents acting on the renin |
14 (9.3%) |
Analgesics |
2 (1.3%) |
Antibacterials for systemic use |
2 (1.3%) |
Antidiarrheals, intestinal antiinflammatory/antiinfective agents |
14 (9.3%) |
Antiemetics and antinauseants |
1 (0.7%) |
Antiepileptics |
1 (0.7%) |
Antiinflammatory and antirheumatic products |
2 (1.3%) |
Antithrombotic agents |
2 (1.3%) |
Antivirals for systemic use |
2 (1.3%) |
Beta blocking agents |
1 (0.7%) |
Calcium channel blockers |
16 (10.6%) |
Cardiac therapy |
6 (4.0%) |
Corticosteroids for systemic use |
1 (0.7%) |
Cough and cold preparations |
1 (0.7%) |
Diuretics |
7 (4.6%) |
DRUGS FOR ACID RELATED DISORDERS |
48 (31.8%) |
Drugs for functional gastrointestinal disorders |
2 (1.3%) |
Endocrine therapy |
1 (0.7%) |
Lipid modifying agents |
9 (6.0%) |
Nasal preparations |
2 (1.3%) |
Other drugs for disorders of the musculo |
1 (0.7%) |
Pituitary and hypothalamic hormones |
1 (0.7%) |
Psychoanaleptics |
8 (5.3%) |
Psycholeptics |
3 (2.0%) |
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
1 (0.7%) |
VASOPROTECTIVES |
3 (2.0%) |
#sources interactions
tbl_summary(
comed_atk, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1",
"OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19",
"CYP3A", "absorption"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 151 |
BCRP |
|
Modéré |
1 (0.7%) |
Non |
104 (68.9%) |
Oui |
46 (30.5%) |
P-gp |
|
Modéré |
9 (6.0%) |
Non |
104 (68.9%) |
Oui |
38 (25.2%) |
MATE1 |
|
Non |
144 (95.4%) |
Oui |
7 (4.6%) |
MRP2 |
|
Non |
150 (99.3%) |
Oui |
1 (0.7%) |
OAT3 |
|
Non |
151 (100.0%) |
OATP1 |
|
Non |
151 (100.0%) |
OATP1B1 |
|
Non |
151 (100.0%) |
OATP1B3 |
|
Non |
151 (100.0%) |
OTC2 |
|
Non |
151 (100.0%) |
CYP2C8 |
|
Faible |
1 (0.7%) |
Non |
150 (99.3%) |
CYP2C9 |
|
Modéré |
1 (0.7%) |
Non |
150 (99.3%) |
CYP2C19 |
|
Non |
151 (100.0%) |
CYP3A |
|
Faible |
7 (4.6%) |
Modéré |
10 (6.6%) |
Non |
130 (86.1%) |
Oui |
3 (2.0%) |
Puissant |
1 (0.7%) |
absorption |
|
Absoption HE |
2 (1.3%) |
Absorption |
17 (11.3%) |
Non |
117 (77.5%) |
Oui |
1 (0.7%) |
pH gastrique |
14 (9.3%) |
##interactions comed sur comed
comed_comed<-filter(analyse_pharma, c(type_interaction=="Comédication sur comédication"))
tbl_summary(
comed_comed, include = c("risque_interaction", "anticancereux_concerne", "comedication_concernee"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 24 |
risque_interaction |
|
Diminution efficacité comédication |
19 (79.2%) |
Majoration toxicité ou diminution efficacité comed |
2 (8.3%) |
Potentialisation d'EI |
3 (12.5%) |
anticancereux_concerne |
|
Bisoprolol |
1 (14.3%) |
Candésartan |
1 (14.3%) |
Doxycycline |
1 (14.3%) |
Escitalopram |
1 (14.3%) |
Formotérol |
1 (14.3%) |
Insuline |
1 (14.3%) |
Tramadol |
1 (14.3%) |
Unknown |
17 |
comedication_concernee |
|
Amiodarone |
1 (4.2%) |
Bétaxolol |
1 (4.2%) |
Calcium |
1 (4.2%) |
CARBOLEVURE |
1 (4.2%) |
Diosmectite |
7 (29.2%) |
FERO-GRAD VITAMINE C |
1 (4.2%) |
GAVISCON |
7 (29.2%) |
Octreotide |
2 (8.3%) |
Racécadotril |
1 (4.2%) |
Siméticone |
1 (4.2%) |
Zopiclone, bromazépam, hydroxyzine, alprazolam |
1 (4.2%) |
#sources interactions
tbl_summary(
comed_comed, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1",
"OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19",
"CYP3A", "absorption"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 24 |
BCRP |
|
Non |
24 (100.0%) |
P-gp |
|
Non |
24 (100.0%) |
MATE1 |
|
Non |
24 (100.0%) |
MRP2 |
|
Non |
24 (100.0%) |
OAT3 |
|
Non |
24 (100.0%) |
OATP1 |
|
Non |
24 (100.0%) |
OATP1B1 |
|
Non |
24 (100.0%) |
OATP1B3 |
|
Non |
24 (100.0%) |
OTC2 |
|
Non |
24 (100.0%) |
CYP2C8 |
|
Non |
24 (100.0%) |
CYP2C9 |
|
Non |
24 (100.0%) |
CYP2C19 |
|
Non |
24 (100.0%) |
CYP3A |
|
Non |
23 (95.8%) |
Oui |
1 (4.2%) |
absorption |
|
Absorption |
17 (70.8%) |
Non |
6 (25.0%) |
Oui |
1 (4.2%) |
##interactions atk sur atk
atk_atk<-filter(analyse_pharma, c(type_interaction=="Anticancéreux sur anticancéreux"))
tbl_summary(
atk_atk, include = c("risque_interaction", "anticancereux_concerne", "comedication_concernee"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 5 |
risque_interaction |
|
Diminution efficacité anticancéreux |
2 (40.0%) |
Majoration toxicité anticancéreux |
3 (60.0%) |
anticancereux_concerne |
|
Crizotinib |
1 (20.0%) |
Osimertinib |
2 (40.0%) |
Tépotinib |
1 (20.0%) |
Tramétinib |
1 (20.0%) |
comedication_concernee |
|
Crizotinib |
1 (20.0%) |
Dabrafénib |
1 (20.0%) |
Osimertinib |
2 (40.0%) |
Tépotinib |
1 (20.0%) |
#sources interactions
tbl_summary(
atk_atk, include = c("BCRP", "P-gp", "MATE1", "MRP2", "OAT3", "OATP1",
"OATP1B1", "OATP1B3", "OTC2", "CYP2C8", "CYP2C9", "CYP2C19",
"CYP3A", "absorption"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 5 |
BCRP |
|
Non |
5 (100.0%) |
P-gp |
|
Non |
2 (40.0%) |
Oui |
3 (60.0%) |
MATE1 |
|
Non |
5 (100.0%) |
MRP2 |
|
Non |
5 (100.0%) |
OAT3 |
|
Non |
5 (100.0%) |
OATP1 |
|
Non |
5 (100.0%) |
OATP1B1 |
|
Non |
5 (100.0%) |
OATP1B3 |
|
Non |
5 (100.0%) |
OTC2 |
|
Non |
5 (100.0%) |
CYP2C8 |
|
Non |
5 (100.0%) |
CYP2C9 |
|
Non |
5 (100.0%) |
CYP2C19 |
|
Non |
5 (100.0%) |
CYP3A |
|
Faible |
1 (20.0%) |
Non |
2 (40.0%) |
Oui |
2 (40.0%) |
absorption |
|
Non |
5 (100.0%) |
#Analyse des interactions avec TAC
##chargement des données
analyse_tac <- read_excel("analyse_tac.xlsx")
###descriptif
tbl_summary(
analyse_tac, include = c("type_traitement","intervention_pharmacien","nom"),
statistic = all_continuous() ~ "{median} [{min} - {max}]",
digits=all_categorical()~ c(0,1)
)
Characteristic |
N = 247 |
type_traitement |
|
Alimentation |
11 (4.5%) |
Apithérapie |
4 (1.6%) |
Aromathérapie |
9 (3.6%) |
Aucun |
88 (35.6%) |
Complément alimentaire |
91 (36.8%) |
Dispositif médical |
1 (0.4%) |
Elixir |
1 (0.4%) |
Gemmothérapie |
1 (0.4%) |
Homéopathie |
37 (15.0%) |
Mycothérapie |
2 (0.8%) |
Phytothérapie |
2 (0.8%) |
intervention_pharmacien |
|
Absence d'interaction |
1 (0.9%) |
Contre-indiquée si porteur de PAC |
1 (0.9%) |
Déconseillée |
83 (72.2%) |
Déconseillée en gélule |
1 (0.9%) |
Ok |
24 (20.9%) |
Prise à 2h de distance |
5 (4.3%) |
Unknown |
132 |
nom |
|
100% FPP (extrait fermenté de papaye) de IMMUNE’AGE |
1 (0.6%) |
ACEROLA C-max |
1 (0.6%) |
Aceticum acidum 15CH |
1 (0.6%) |
Ail de LA ROYALE |
1 (0.6%) |
ALVITYL |
1 (0.6%) |
ALVITYL Vitalité |
1 (0.6%) |
ANACAPS |
1 (0.6%) |
Apis 15CH |
1 (0.6%) |
Apis mellifica 8DH, Aurum muriaticum natronatum 7DH, Avena Sativa 4DH, Hypericum Perforatum 4DH, Ignatia amara 5DH, Phosphoricum acidum 5DH |
1 (0.6%) |
Aragonite D1 50%, calcarea carb D4 25%, quercus D3 |
1 (0.6%) |
Argile par voie orale |
2 (1.3%) |
Armoise |
1 (0.6%) |
Artémisia Annua de HERBAL D-TOX |
1 (0.6%) |
ARTERIA |
1 (0.6%) |
Ashwagandha |
1 (0.6%) |
BERBERIS RADIX D3, CARDUS MARIANUS D2, CHELIDONIUM RADIX D3, COLCHICUM D2, CURCUMA D2, SULFUR D8, TARAXACUM STANNO CULTUM D3 |
1 (0.6%) |
BERROCA |
2 (1.3%) |
BIBHITAKI FRUIT |
1 (0.6%) |
BION Vitalité |
1 (0.6%) |
BIOTIC P7 |
1 (0.6%) |
BIOTICS 3B-G (vitamine B) |
1 (0.6%) |
Bovista gigantea 5CH |
1 (0.6%) |
BROMELAINE |
1 (0.6%) |
Charbon végétal activé |
1 (0.6%) |
Chelidonium D1, Curcuma D1, Taraxacum stanno cultum D3 |
1 (0.6%) |
China 9CH |
1 (0.6%) |
Chlorella + Spiruline de Biotona |
1 (0.6%) |
Chlorure de magnésium et vitamine B6 |
2 (1.3%) |
CHRYSANTELLUM |
1 (0.6%) |
Compléments alimentaires |
1 (0.6%) |
CORIOLUS VERSICOLOR EXTRAKT |
1 (0.6%) |
Corrosol |
1 (0.6%) |
Cuprum metallicum 9CH |
1 (0.6%) |
Curcuma + poivre noir de LA ROYALE |
1 (0.6%) |
D-Mulsion FORTE (vitamine D) de BIOTICS RESEARCH |
1 (0.6%) |
D3 PROTECT (vitamine D3) |
1 (0.6%) |
Desmodium |
2 (1.3%) |
Dilution 5, 7 et 9CH |
1 (0.6%) |
Epices, thés, infusions, graines… |
1 (0.6%) |
EPS desmodium |
1 (0.6%) |
EPS rhodiole et mélisse |
1 (0.6%) |
ERGY D (Vit D) |
2 (1.3%) |
ERGYMAG (Mg + zn) |
1 (0.6%) |
ERGYMAG (Mg + Zn) |
1 (0.6%) |
ERGYSIL (ortie, silicium, sélénium) |
1 (0.6%) |
Ferments lactiques des laboratoire Dieti Natura |
1 (0.6%) |
Ferrum metallicum 7 CH |
1 (0.6%) |
Ferrum sid D10, Phosphorus D8, Silicea D12 W788 60cc dilution |
1 (0.6%) |
Fleurs de Bach |
1 (0.6%) |
FLEXOFYTOL (curcuma) |
1 (0.6%) |
Floracare XL (bifidobactéries et des lactobacilles) de BIOTICS RESEARCH |
1 (0.6%) |
Gelée royale |
1 (0.6%) |
Glutathion |
1 (0.6%) |
Glutathion Liposomé + de HOD |
1 (0.6%) |
Graine de plantain |
1 (0.6%) |
HAIR VOLUME |
1 (0.6%) |
Huile essentielle de ravintsara |
1 (0.6%) |
Huile essentielle de Romarin à verbénone |
1 (0.6%) |
Huile essentielle de Tea tree |
1 (0.6%) |
Huile essentielle de thym |
1 (0.6%) |
Huile végétale de millepertuis |
2 (1.3%) |
Huile végétale de rose musquée |
1 (0.6%) |
Huille essentielle d'helichryse |
1 (0.6%) |
Huille essentielle de lavandin |
1 (0.6%) |
IMMUN ACTIFS |
1 (0.6%) |
Imussentiel fort |
1 (0.6%) |
Influenzinum 15CH |
1 (0.6%) |
INTENZYME FORTE |
1 (0.6%) |
KIDNEY CLEANSE |
1 (0.6%) |
KLARELINE |
1 (0.6%) |
Lachesis 9CH, phosphorus 9CH, nux vomica 9CH |
1 (0.6%) |
LACTIBIANE REFERENCE |
1 (0.6%) |
LENODIAR |
1 (0.6%) |
Levure de riz rouge, oméga 3 et CoQ10 |
1 (0.6%) |
Lithothamne de LA ROYALE |
1 (0.6%) |
Lycopodium clavatum 15CH |
1 (0.6%) |
Lycopodium clavatum D10 |
1 (0.6%) |
Macérat de gui de LA ROYALE |
1 (0.6%) |
MAGN ACTIFS |
2 (1.3%) |
Maitake |
1 (0.6%) |
Medulo D8 |
1 (0.6%) |
Mélisse en gélules ou tisanes |
1 (0.6%) |
MENO ACTIFS |
1 (0.6%) |
Miel, propolis |
1 (0.6%) |
Natrum muriaticum 15 CH |
1 (0.6%) |
Natrum sulfuricum 15CH |
1 (0.6%) |
Nux vomica 9CH |
1 (0.6%) |
Oméga 3 |
1 (0.6%) |
OMEGA 3 de Solgar |
1 (0.6%) |
OMEGABIANE DHA |
1 (0.6%) |
OPTIFLOR |
1 (0.6%) |
Phosphorus 30CH |
1 (0.6%) |
Physiomance D-nat |
1 (0.6%) |
Physiomance magnesium b6+ |
1 (0.6%) |
Physiomance sélénium+ |
1 (0.6%) |
Physiomance zinc |
1 (0.6%) |
Physiomance Ubiquinol 3 |
1 (0.6%) |
Plumbum mellitum D12 30g Trit |
1 (0.6%) |
Pollen de fleurs |
1 (0.6%) |
Pollen en pelotes Bio Miel Besacier |
1 (0.6%) |
PROCARTIL (glucosamine, chondrotoïne, manganèse, cuivre) |
1 (0.6%) |
PROPOMAX (propolis verte et brune bio, bioflavonoides et artepilline c) |
1 (0.6%) |
Prostate 8DH |
2 (1.3%) |
Psyllium |
1 (0.6%) |
RENFORSTIM |
1 (0.6%) |
Ribes nigrum 1DH |
1 (0.6%) |
Ruscus aculeatus 4DH |
1 (0.6%) |
Selenium ACE Optimum 50+ |
1 (0.6%) |
SEREMAG (magnésium, taurine et vitamine B6) |
1 (0.6%) |
Serum de Yersin 9 CH |
1 (0.6%) |
Sève de bouleau 1DH |
1 (0.6%) |
STRESS’O (rhadiola, choline, lavande vrai) de PHYSIOSENS |
1 (0.6%) |
Sulfate de magnésium |
1 (0.6%) |
Sulfurum 7CH |
1 (0.6%) |
Teinture mère de Calendula |
2 (1.3%) |
Teinture mère de Dionaea Muscipula |
1 (0.6%) |
Teinture mère GINKGO BILOBA |
1 (0.6%) |
TEMPORAL (Levure de riz rouge, policaosanol, CoQ10) |
1 (0.6%) |
Teoliance hpi 60 |
1 (0.6%) |
Thé au citron ou orange-canelle |
1 (0.6%) |
Thé noir |
1 (0.6%) |
Thymuline 4CH |
1 (0.6%) |
THYROSTIM (L-thyroxine, vit C, vit D, zinc…) de Copmed |
1 (0.6%) |
Tisane |
1 (0.6%) |
Tisane d’olivier et d’hibiscus |
1 (0.6%) |
Tisane de thym et sauge |
2 (1.3%) |
Tisane verveine |
1 (0.6%) |
Tuberculinum 15CH |
1 (0.6%) |
UNIBIANE HCA (garcinia) |
1 (0.6%) |
UNIBIANE R-α lipoïque |
1 (0.6%) |
Vitamine B12 |
1 (0.6%) |
Vitamine C |
2 (1.3%) |
VITAMINE C 1000 mg |
1 (0.6%) |
Vitamine C liposomale de Biocyte |
1 (0.6%) |
Vitamine C liposomale de LA ROYALE |
1 (0.6%) |
Vitamine D |
1 (0.6%) |
VITAMINE D3 |
1 (0.6%) |
Vitamine d3 + k2 de Sunday Naturel |
1 (0.6%) |
VITAMINE D3 2000UI |
1 (0.6%) |
VITAMINE D3 800UI de Sante verte |
1 (0.6%) |
Vitamine K2 |
1 (0.6%) |
VITAMINE K2 |
1 (0.6%) |
Weleda c692 |
1 (0.6%) |
Weleda c720 |
1 (0.6%) |
Zinc |
3 (1.9%) |
Zinc (amino chelate) |
1 (0.6%) |
Unknown |
88 |